RNA Therapeutics CDMO Market Size to Reach USD 40.68 Billion by 2035 at a CAGR of 9.86%

The article projects the U.S. RNA therapeutics CDMO market will reach $15.68 billion by 2035, while Europe is forecast to reach $10.73 billion. Growth is attributed to increased mRNA manufacturing outsourcing, expanded lipid nanoparticle capacity, and AI-driven manufacturing adoption. The outlook is supportive for RNA-focused contract development and manufacturing organizations, but the article provides no near-term company financial results or market-moving catalysts.

Analysis

This is a low-confidence, long-duration thematic datapoint rather than a near-term earnings catalyst: the forecast is not independently validated and broad RNA-CDMO growth is already embedded in premium life-sciences-tools multiples. The investable bottleneck is not generic mRNA production but validated lipid nanoparticle (LNP) formulation, aseptic fill-finish, analytical release testing, and regulatory-grade scale-up. Those capabilities create switching costs and can support utilization-led margin expansion once late-stage RNA pipelines convert, but capacity built for pandemic-era demand remains a material overhang.

The likely public-market beneficiaries are diversified outsourced-manufacturing platforms with biologics and sterile-injectables infrastructure—Lonza (LONN.SW), Thermo Fisher (TMO), Danaher (DHR), Catalent (CTLT, subject to Novo transaction completion), and potentially Samsung Biologics (207940.KS)—rather than smaller single-technology suppliers. AI-manufacturing claims should be discounted: near-term value accrues primarily through lower batch-failure rates and faster deviation investigation, neither of which materially changes revenue until customer programs reach commercial scale. Specialized LNP/IP suppliers could gain disproportionately, but most exposure is private or buried within broader portfolios.

Over the next 1-3 months, the key falsifier is not market-size research but evidence of backlog conversion: RNA-related bookings, commercial-scale capacity reservations, and utilization commentary during earnings. Over 6-18 months, durable upside requires non-COVID RNA approvals in oncology, rare disease, or protein-replacement indications; repeated trial failures, reimbursement resistance, or excess CDMO capacity would compress the scarcity premium. Consensus may overestimate the speed of mRNA outsourcing while underestimating that only a handful of validated facilities can capture regulated commercial volumes.

Key Decisions for Investors

• No directional trade solely on this forecast; create an earnings watchlist for TMO, DHR, LONN.SW and 207940.KS, requiring disclosed RNA/LNP order growth or utilization improvement before adding exposure.
• Prefer a 6-18 month relative-value position long TMO or DHR versus an equal-weight short XBI only after confirmation of RNA-related bookings: diversified service revenue and installed-base pull-through reduce binary clinical-trial risk versus pre-revenue RNA developers.
• For LONN.SW, consider accumulation on a 10-15% drawdown only if management confirms incremental biologics/RNA capacity is contracted rather than speculative; downside risk is prolonged underutilization and multiple de-rating if customer reservations do not convert.
• Monitor CTLT transaction-close and customer-retention disclosures rather than treating it as a clean RNA-CDMO exposure; integration disruption or program transfers following Novo ownership would alter competitive capacity dynamics for TMO, DHR and Lonza.